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Abstract
Background: The pathological features in Alzheimer’s disease (AD) brain include the accumulation and deposition
of β-amyloid (Aβ), activation of astrocytes and microglia and disruption of cholinergic neurotransmission. Since the
topographical characteristics of these different pathological processes in AD brain and how these relate to each
other is not clear, this motivated further exploration using binding studies in postmortem brain with molecular
imaging tracers. This information could aid the development of specific biomarkers to accurately chart disease
progression.
Results: In vitro binding assays demonstrated increased [3H]-PIB (fibrillar Aβ) and [3H]-PK11195 (activated microglia)
binding in the frontal cortex (FC) and hippocampus (HIP), as well as increased binding of [3H]-L-deprenyl (activated
astrocytes) in the HIP, but a decreased [3H]-nicotine (α4β2 nicotinic acetylcholine receptor (nAChR)) binding in the
FC of AD cases compared to age-matched controls. Quantitative autoradiography binding studies were also
performed to investigate the regional laminar distributions of [3H]-L-deprenyl, [3H]-PIB as well as [125I]-α-
bungarotoxin (α7 nAChRs) and [3H]-nicotine in hemisphere brain of a typical AD case. A clear lamination pattern
was observed with high [3H]-PIB binding in all layers and [3H]-deprenyl in superficial layers of the FC. In contrast,
[3H]-PIB showed low binding to fibrillar Aβ, but [3H]-deprenyl high binding to activated astrocytes throughout the
HIP. The [3H]-PIB binding was also low and the [3H]-deprenyl binding high in all layers of the medial temporal gyrus
and insular cortex in comparison to the frontal cortex. Low [3H]-nicotine binding was observed in all layers of the
frontal cortex in comparison to layers in the medial temporal gyrus, insular cortex and hippocampus.
Immunohistochemical detection in the AD case revealed abundant glial fibrillary acidic protein positive (GFAP+)
reactive astrocytes and α7 nAChR expressing GFAP+ astrocytes both in the vicinity and surrounding Aβ neuritic
plaques in the FC and HIP. Although fewer Aβ plaques were observed in the HIP, some hippocampal
GFAP+ astrocytes contained Aβ-positive (6 F/3D) granules within their somata.
Conclusions: Astrocytosis shows a distinct regional pattern in AD brain compared to fibrillar Aβ, suggesting that
different types of astrocytes may be associated with the pathophysiological processes in AD.
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Introduction
The gradual accumulation of β-amyloid (Aβ) peptides in
the brain, varying in size and state of aggregation, is sug-
gested to play a central role in Alzheimer’s disease (AD),
triggering a cascade of neurodegenerative changes in the
brain. These include neurofibrillary tangle formation, the
activation and exacerbation of inflammatory processes,
impairment of neurotransmitter signaling, and the per-
turbation of synaptic functions resulting in the death of
neurons in brain areas associated with learning and
memory [1,2].
The rapid development of molecular imaging in the
past decade has provided valuable new tools for the
understanding of complex disease mechanisms in AD.
Positron emission tomography (PET) imaging of the
brain using amyloid tracers has provided evidence that
the accumulation of fibrillar Aβ in the brain occurs early
on in the disease course, preceding progressive changes
in metabolic activity and structure, which occur closer
to the manifestation of clinical symptoms in AD [3-9].
AD-associated inflammation has been widely described
by pathological examination of brain tissue from AD
patients demonstrating abundant activated microglia in
Aβ plaques and increased numbers of reactive astrocytes
surrounding Aβ plaques [10-15]. However, it is not clear
whether the inflammatory response detected in postmor-
tem brain was a cause or a consequence of disease pro-
gression. It is suggested that the inflammatory processes
in AD may have contrasting roles where, for instance,
activated glia not only eliminate Aβ plaques via phago-
cytosis but may also initiate a proinflammatory cascade
that results in the release of potentially neurotoxic sub-
stances such as cytokines, complement components,
various free radicals, and nitric oxide, all of which may
contribute to further neuronal dysfunction and cell death
[16]. Findings from the most recent multitracer PET stud-
ies in patients with mild cognitive impairment (MCI) and
mild AD indicate that astrocytosis is similar to Aβ accu-
mulation, an early phenomenon in AD, but follows a
different spatial and temporal pattern than fibrillar Aβ
deposition and impaired synaptic activity as measured by
glucose metabolism [17].
Although in vivo imaging methods provide valuable
quantitative information with regards to disease progres-
sion and understanding the complex pathology in AD
neurodegeneration, it is also important to study in aut-
opsy brain how the different pathological processes are
related.
In the present study, we investigated the relationship
between regional neuroinflammatory processes, fibrillar
Aβ deposition, and disturbances in cholinergic neuro-
transmission in AD brain. Binding studies were carried
out in postmortem brains from a group of age-matched
AD and non-demented control cases with the radioligands
[3H]-L-deprenyl (activated astrocytes), [3H]-PIB (fibrillar
Aβ), [3H]-PK11195 (microglia) as well as [125I]-α-bungaro-
toxin (α7 nicotinic receptors, nAChRs) and [3H]-nicotine
(α4β2 nAChRs). We also applied an in vitro imaging mul-
titracer concept in order to characterize and compare the
laminar distributions of activated astrocytes, fibrillar Aβ,
as well as α7 and α4β2 nAChRs in hemisphere brain
sections of an AD patient who was clinically followed
at regular intervals until death.
Methods
Subjects
Postmortem brain tissues from the superior frontal gyrus
and the hippocampus from 11 AD cases (age 75.2 ± 2.7
years; postmortem delay 15.9 ± 3.2 h; Braak stages 5 to
6), and 13 age-matched controls (age 73.9 ± 3.0 years;
postmortem delay 18.5 ± 2.5 h; Braak stages 1 to 2) were
obtained from the Brain Bank at Karolinska Institutet
and the Netherlands Brain Bank. Each AD case had a clin-
ical diagnosis of AD confirmed by pathological examin-
ation according to criteria from the National Institute
of Neurological and Communicative Disorders and Stroke
and the Alzheimer’s disease and Related Disorders Associ-
ation (NINCDS-ADRDA) and Consortium to Establish a
Registry for Alzheimer’s disease (CERAD) workgroups.
The control cases had no history of psychiatric or neuro-
logical disorders or neuropathology indicating dementia.
The main cause of death among the AD cases was bron-
chopneumonia and for controls, myocardial infarction.
Permission to use autopsy brain material in experimental
procedures was granted by the Regional Human Ethics
committee in Stockholm and the Swedish Ministry of
Health. All material and data collected by the Netherlands
Brain Bank were obtained on the basis of written informed
consent.
Binding assays
Brain samples from the frontal cortex and hippocampus
of AD and control cases were homogenized in cold phos-
phate-buffered saline (PBS) pH 7.0 containing protease
inhibitors. Triplicate samples of prepared crude homoge-
nates were incubated with 1 nM [3H]-PIB (SA 68 Ci/
mmol), 10 nM [3H]-L-deprenyl (SA 80 Ci/mmol), 5.0 nM
[3H]-PK11195 (specific activity 83.4 Ci/mmol, American
Radiolabeled Chemicals, St. Louis, MO, USA), as previ-
ously described [6,18]. For the [3H]-nicotine (5 nM; SA 75
Ci/mmol) and [125I]-α-bungarotoxin (2 nM; SA 108.8 Ci/
mmol) binding assays to α4β2 and α7 nAChRs, res-
pectively, membrane fractions were prepared by ho-
mogenization in 0.32 M sucrose, centrifugations and
resuspension in binding buffer prior to incubations.
Specific binding was expressed in fmol/mg tissue or
fmol/mg protein.
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Cryosectioning
From the set of AD cases described above, a 61-year-old
AD case (17 h postmortem delay; Braak stage 6) was
selected for large-section cryomicrotomy.
Guided by an atlas of the human brain [19], 5-mm thick
coronal planes situated at a distance of 30 to 40 mm from
the most anterior part of the brain were chosen for this
study. From these planes, 80-μm thick sections from the
left hemisphere were cut at −20°C and thaw-mounted on
gelatin-coated 200 × 150 mm2 glass plates, as described
previously [20].
Whole hemisphere autoradiography
Brain sections were thawed at room temperature (RT)
prior to incubations. Autoradiography binding studies
were performed by preincubating sections for 15 minutes
in PBS buffer (pH 7.4) followed by incubation with 5 ml of
respective ligand; 1 nM [3H]-PIB (specific activity, SA 68
Ci/mmol, custom synthesis; GE Healthcare, Freiburg,
Germany) for 45 minutes [21]; 10 nM [3H]-L-deprenyl
(specific activity 80 Ci/mmol, Larodan Fine Chemicals AB,
Malmö, Sweden) for 1 h [22]; 5.0 nM [3H]-nicotine (spe-
cific activity 75 Ci/mmol, NEN Life Science Products,
Dreiech, Germany) for 40 minutes [23]; and 2 nM [125I] α-
bungarotoxin (specific activity 108.8 Ci/mmol, Perkin
Elmer, Waltham, MA, USA) for 30 minutes [24]. To deter-
mine non-specific binding for each radioligand, adjacent
sections were incubated with 1 μM of unlabeled PIB, 1
μM unlabeled deprenyl, 100 μM (−) nicotine or 1 μM un-
labeled α-bungarotoxin (Tocris Bioscience, Bristol, UK),
respectively. The binding reactions were terminated by
rinsing sections 3 × 5 minutes in cold buffer and a brief
rinse in deionized distilled water. Sections were air dried
for at least 48 h and placed together with calibrated trit-
ium standards in autoradiography cassettes and exposed
to Fujifilm BAS-2500 imaging plates (Science Imaging
Scandinavia AB, Nacka, Sweden) or to tritium-sensitive
film (Amersham Hyper film MP; GE Healthcare) for the
appropriate length of time. For [125I]-α-bungarotoxin
autoradiography, different concentrations of [125I]-α-bun-
garotoxin (0.5 to 5 nM), serving as a standard, were ap-
plied onto a filter paper and exposed together with the
sections to Kodak Biomax MR film (Sigma, St Louis, MO,
USA) for 14 days.
Quantitative analysis of autoradiographic images
All laminar identification examinations were carried out
with guidance of a classical atlas Brodman [25] and Nissl
stained sections, and further assisted by autoradiograms
of [3H]-L-deprenyl binding, since [3H]-L-deprenyl has
earlier been shown to have a clear demarcation between
different laminae in human brain cortex [22,26].
For quantification, the optical densities were measured
using computer-assisted image analysis that digitized the
light intensity into 256 levels (Imteck Vision, Uppsala,
Sweden). A calibration curve was obtained from a set
of films with known optical densities (OD) (KODAK
Wratten gelatin filters). The unit area (pixel) of meas-
urement was about 180 μm2. The digitized picture was
displayed on a color monitor and regions for calculation
of mean OD were selected. For each region, three autora-
diograms were analyzed and two readings were taken.
The binding density (fmol/mg tissue) corresponding to
the autoradiography obtained gray values in the cortical
areas was determined from the micro scale standards that
contained a known amount of radioactivity per mass of
tissue, and divided by the specific radioactivity of each
ligand. To measure the laminar distribution of binding
densities in the cortex, averaged gray levels of 20 or
more consecutive lines (corresponding to a total width
of ≥0.65 mm) perpendicular to the entire cortical depth
from the pial surface to the white matter were determined
as described by [23]. Profiles were created at the position
of each examined cortical area where the highest quality
of tissue was observed. Accordingly, differences could
occur in the width of the same layer within one cortical
region. The entire depth of the cortex was standardized to
100% to account for variances in the absolute cortical
depth, due to a slight change of angle during tissue
sectioning. The non-specific binding, which did not show
any laminar pattern, was subtracted.
Immunohistochemistry
Immunohistochemistry was performed on the single AD
case by pretreating sections with formic acid (88%) for 10
minutes or with ethylenediaminetetra-acetic acid, (EDTA)
for 20 minutes. For antigen retrieval, sections were heated
in a microwave oven (700 W) for 10 minutes in 0.05 M
citrate-buffered saline (pH 6.0) followed by a blocking
step. The sections were incubated with antibodies specific
for Aβ 6 F/3D (1:200 to 1:400; Dako, Glostrup, Denmark)
or 4G8 (1:200, Chemicon International, Temecula, CA,
USA), Tau AT8 (1:500, Innogenetics, Gent, Belgium),
microglia CD68 (1:100, Dako), glial fibrillary acidic pro-
tein (GFAP; 1:300 to 1:500, Dako), mouse monoclonal
α7 nAChR mAb 306 antibody (1:1,000, Sigma-Aldrich), and
biotin-conjugated α-bungarotoxin (Invitrogen, Carlsbad,
CA, USA). Following incubation with biotinylated second-
ary antibodies and washes, the VECTASTAIN Elite ABC
(Vector Laboratories, Burlingame, CA, USA), chromogen
Vector SG substrate or EnVision™ G|2 System/AP Rabbit/
Mouse (Permanent Red visualization (Dako) kits, respect-
ively were used for detection. Controls consisted of brain
sections treated with either non-immune serum or omission
of primary antibody.
For analysis of histological findings, an image analysis
system was utilized that allowed processing of images
from a video camera attached to a microscope. The
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percentage of astrocytes expressing the α7nAChR sub-
unit was assessed in double-stained sections as previ-
ously described [27]. For each brain section, six strips
(with a total width of 600 μm) that extended from the
pial surface to the border with the white matter were
chosen from the top, middle, and bottom of the sections
for evaluation.
Results
Comparison of binding levels for fibrillar amyloid,
reactive astrocytes, and activated microglia in relation to
α4β2 and α7 nicotinic receptors in AD and control brain
Significantly higher binding levels of [3H]-PIB were
measured both in the frontal cortex (P <0.0007) and in
the hippocampus (P <0.002) of AD cases compared to
age-matched controls (Figure 1A,F). Similarly, significant
increases in the binding of [3H]-L-deprenyl in the hippo-
campus (P <0.03) and [3H]-PK11195 in the frontal cortex
(P <0.002) were observed in AD cases (Figure 1C,G). [3H]-
Nicotine binding was significantly reduced in the frontal
cortex (P <0.02) of AD cases (Figure 1D), while no signifi-
cant changes in [125I]-α-bungarotoxin binding were ob-
served in either the frontal or hippocampus of AD cases
relative to controls (Figure 1E,J).
Laminar autoradiographical distributions fibrillar amyloid,
reactive astrocytes, and nicotinic receptor subtypes
in AD brain
Autoradiography binding in coronal hemisphere brain
sections from the AD case showed varied distribution
Figure 1 Comparison of binding levels of (A, F) [3H]-PIB (fibrillar β-amyloid), (B, G) [3H]-L-deprenyl (activated astrocytes), and (C, H)
[3H]-PK11195 (activated microglia), as well as (D, I) [3H]-nicotine and (E, J) [125I]-α-bungarotoxin to α4 and α7 nicotinic acetylcholine
receptor (nAChR) subtypes, respectively, in the frontal cortex and hippocampus of Alzheimer’s disease (AD) cases (open circles) and
age-matched controls (filled circles). Data obtained from the binding assays are expressed in fmol/mg tissue or protein (means ± SEM), and
were analyzed by one-way analysis of variance (ANOVA) followed by Bonnferroni’s or Dunnet’s post hoc tests to compare statistical differences
between control and AD cases. *P <0.05; **P <0.01; ***P <0.001.
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profiles for [3H]-PIB, [3H]-L-deprenyl, [3H]-nicotine, and
[125I]-α-bungarotoxin as illustrated in the pseudocolored
images in Figure 2.
Next, we quantified the laminar distributions for each
ligand in different layers of the cerebral cortex. [3H]-PIB
showed high binding (350 to 500 fmol/mg tissue) in all
layers of the superior frontal cortex (Figure 3A), while in
contrast, [3H]-L-deprenyl binding showed high binding
levels (400 fmol/mg tissue) only in the superficial layers
(lamina I and II) of the frontal cortex (Figure 3B). The
medial temporal gyrus and insular cortex exhibited simi-
lar high [3H]-L-deprenyl binding densities (400 fmol/mg
tissue) in all layers, and equivalent lower [3H]-PIB bind-
ing densities (150 to 250 fmol/mg tissue) (Figures 4A,B
and 5A,B). Among the cortical regions, the frontal
cortex showed lower [3H]-nicotine binding (2 fmol/mg
tissue), and more equal laminar binding in comparison
to both the medial temporal gyrus and insular cortex
(Figures 3C, 4C and 5C). The [125I]-α-bungarotoxin au-
toradiograms showed high background levels in cortical
regions, which prevented further quantitative analysis of
the specific binding (data not shown).
The hippocampal subregions examined are delineated
in Figure 6A. [3H]-PIB showed low and uniform binding
(180 to 200 fmol/mg tissue), while [3H]-L-deprenyl
showed uniformly high binding (400 fmol/mg tissue)
throughout the hippocampus (Figure 6B,C). [125I]-α-
Bungarotoxin binding was observed mainly in the dentate
gyrus, in contrast to [3H]-nicotine binding (Figure 6D,E).
Topographical distributions of reactive astrocytes within
the frontal cortex and hippocampus of AD brain by
immunohistochemical staining
Neuropathological confirmation of the AD case showed
characteristic AD neurodegenerative changes (deposition
of Aβ and phosphorylated tau protein, the presence of
activated microglia and reactive astrocytes) in the brain
(Additional file 1: Figure S1).
To relate the laminar [3H]-L-deprenyl autoradiography
binding, the distribution of reactive astrocytes within
different layers of the frontal cortex and hippocampal
subregions in the single AD case was examined by im-
munohistochemistry with GFAP as a marker for astro-
cytosis. Differences in the localization and intensity of
GFAP immunoreactive cells were found both within each
region as well as between the regions (Figure 7). The
distribution in the frontal cortex revealed a layer-specific
localization of GFAP+ cells exhibiting heterogeneous
morphologies (Figure 7A). A uniform distribution of react-
ive astrocytes with small somata and dense staining of
GFAP+ neuropil was detected in the superficial (Figure 7B).
In the deeper layers, GFAP+ astrocytic somata and densely
stained neuropil were concentrated around Aβ plaques
(Figure 7C). GFAP+ astrocytes were distributed more
evenly in the cortical layer bordering the white matter
(laminaVI), and very few Aβ plaques were observed in this
region (Figure 7D).
A different staining pattern was observed in the hip-
pocampus, where both GFAP+ astrocyte somata and pro-
cesses surrounding 6 F/3D-positive Aβ plaques and GFAP+
astrocytes containing intracellular vesicles with 6 F/3D ag-
gregates detected (Additional file 2: Figure S2).
In the CA1 alveus and stratum oriens of the hippo-
campus, we observed intensely stained small somata of
GFAP+ astrocytes with immunoreactivity for α7 nAChRs
as well as dense GFAP+/α7 nAChR-positive cellular net-
works (Figure 7E,F). Throughout the CA1 stratum pyr-
amidal, large somata of GFAP+ astrocytes displaying no
immunoreactivity for α7 nAChRs were found as well as
dispersed GFAP+ network fibers (Figure 7G). Differences
in the intensity of immunoreactivity and the number of
GFAP+ astrocytes were detected in the CA1 stratum lacu-
nosum-molecular and the molecular layer of the dentate
gyrus (Figure 7H). In the granular layer, light brown
stained somata of GFAP + astrocytes and weakly stained
GFAP+ network fibers (top layer) were accompanied by
very strong staining of α7 nAChR positive/GFAP+ astro-
cytes (gray hue, bottom layer) (Figure 7I).
Discussion
Aβ deposition in the brain is a pathological hallmark of
AD. In the present study in vitro binding studies in
tissue homogenates showed significantly higher [3H]-PIB
binding in the brain of a cohort of AD subjects com-
pared to non-demented controls and thereby confirmed
earlier observed high in vivo 11C-PIB PET retention in
cortex of AD patients compared to healthy controls [3].
Furthermore, in the current study in vitro imaging of
the cortical laminar distribution pattern for fibrillar Aβ
with [3H]-PIB autoradiography in a single AD case showed
high binding in all layers of the frontal cortex. Earlier
observations from quantitative immunohistochemical
studies in AD autopsy brain have revealed high Aβ-
plaque densities in layers II and III of the temporal and
occipital cortices, while lower densities were reported
in layers V and IV [10,28-31], but with larger plaque
size in layer V [10], suggesting that Aβ plaque deposition
may be intricately linked with cortical organization.
Since 3H-PIB has been found to bind to multiple binding
sites in AD frontal cortex; this could underlie the dif-
ferences between 3H-PIB binding data and quantitative
morphological measurement of Aβ plaques [10,32].
The detection of cerebral β-amyloidosis in vivo in
patients with PET amyloid imaging tracers such as [11C]-
PIB have been shown to correlate well with levels of
fibrillar Aβ measured in AD brain at autopsy [6,33].
Measurement of the distribution of [11C]-PIB retention
based on cytoarchitectonic subtypes of the cerebral cortex
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Figure 2 Representative pseudocolored autoradiographical distributions of (A,B) [3H]-PIB, (C,D) [3H]-L-deprenyl, (E,F) [3H]-nicotine, and
(G,H) [125I]-α-bungarotoxin binding in coronal sections obtained from the frontal cortex and hippocampus of a typical Alzheimer’s
disease (AD) patient at autopsy. The density of the binding increases along the sequence of blue, green, yellow, and red. The pseudocolored
figures are not standardized to each other, since the series of autoradiograms for each ligand were created individually.
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demonstrated that the neocortex with more fully lam-
inar differentiation showed abundant [11C]-PIB retention,
while phylogenetically older limbic areas, such as the
allocortex and the periallocortex, with fewer laminae
appeared less vulnerable to [11C]-PIB retention, when
comparing AD patients with healthy control subjects [34].
Figure 3 Laminar distribution of total binding for (A) [3H]-PIB, (B) [3H]-L-deprenyl, and (C) [3H]-nicotine throughout the entire cortical
depth of the superior frontal gyrus in an Alzheimer’s disease (AD) case. The binding profiles are means created from three consecutive sections.
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Non-random Aβ plaque distribution within cortical areas
could imply that specific neurons or spatial arrangements
of neuronal networks can serve as a substrate for plaque
aggregation, where factors such as the regional concentra-
tion of Aβ, in turn determines the amount of plaque load
in a given area, while the local architectonics of the cortex
Figure 4 Laminar distribution of (A) [3H]-PIB, (B) [3H]-L-deprenyl, and (C) [3H]-nicotine total binding throughout the entire cortical
depth of the medial temporal gyrus in an Alzheimer’s disease (AD) case. The binding profiles are means created from three consecutive sections.
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determines the distribution pattern among brain regions.
This differential cytoarchitectonic vulnerability to Aβ de-
position may underlie the progressive neuropathological
alterations involved in the hierarchical organized central
nervous system in the pathogenesis of AD.
Different forms of Aβ in the brain can elicit activation
and recruitment of microglia and astrocytes. These cells
play a central role in the cellular response to patho-
logical lesions and exercise both neuroprotective and
neurotoxic functions in the brain, mediated by the
Figure 5 Laminar binding distributions for (A) [3H]-PIB, (B) [3H]-L-deprenyl, and (C) [3H]-nicotine throughout the entire cortical depth
of the insular cortex in an Alzheimer’s disease (AD) case. The binding profiles are means created from three consecutive sections.
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Figure 6 Subregional binding distributions for [3H]-PIB, [3H]-L-deprenyl, and [3H]-nicotine and [125I]-α-bungarotoxin within the
hippocampus of an Alzheimer’s disease (AD) case. (A) An illustrative photomicrograph of a Nissl-stained section delineating the
cytoarchitectonic layers of the hippocampus including the alveolar (a), stratum oriens (so), the stratum pyramidale (sp), stratum radiutum (sr),
molecular layer of the dentate gyrus (m), and the Cornu Ammonis areas CA1 to CA4. Modified with permission from Teaktong et al. [65]. The
binding distribution of (B) [3H]-PIB, (C) [3H]-L-deprenyl, (D) [3H]-nicotine, and (E) [125I]-α-bungarotoxin in the hippocampus of an Alzheimer’s
disease (AD) case. The binding profiles are means created from three sections.
Marutle et al. Journal of Neuroinflammation 2013, 10:90 Page 10 of 15
http://www.jneuroinflammation.com/content/10/1/90
secretion of cytokines and chemokines and the binding
of these to their specific receptors [34-37]. Here, we
demonstrated increased levels of both activated micro-
glia and reactive astrocytes in AD frontal cortex and
hippocampus as measured by [3H]-PK11195 and [3H]-L-
deprenyl binding, respectively. In vivo PET studies with
[11C]-PK11195 have demonstrated both increased and
unchanged binding in AD patients compare to healthy
subjects [38,39] and there might be different explana-
tions for discrepancies in findings such as different used
PET protocols, variation in sensitivity of the PET tracer
as well as differences in patient material. Deprenyl is a
selective irreversible monoamine oxidase B (MAO-B) in-
hibitor and is considered to be a sensitive marker for
measuring astrocytosis in the brain, since the MAO-B
enzyme is upregulated in reactive astrocytes, giving rise
to increased regional uptake of deprenyl [40]. A strong
correlation between [3H]-L-deprenyl binding and MAO-
B activity in both AD and non-demented control aut-
opsy brain tissue has previously been reported [41,42].
Figure 7 The topographical distribution of reactive astrocytes within the superior frontal gyrus and hippocampus in an Alzheimer's
disease case. (A) Histological reconstruction of frontal gyrus gray matter made by the superimposition of identical areas of adjacent sections
displaying reactive astrocytes with heterogenous morphologies in the different layers. 6F/3D β-amyloid (Aβ) plaques are in red color, reactive
astrocytes positive for glial fibrillary acidic protein (GFAP+) are brown. Representative areas (B-D) are in the right column. (B) A uniform distribution of
GFAP+ astrocytes (arrows) with small somata and densely stained neuropil in the superficial layers. (C) In the deeper layers, densely stained
GFAP+ astrocytes and neuropil are concentrated around Aβ-neuritic plaques (arrows). (D) In the cortical lamina-VI bordering the white matter,
GFAP+ astrocytes (arrows) were distributed more evenly as very few Aβ-neuritic plaques were observed in this region. (E) Histological reconstruction of
the hippocampal CA1 and the dentate gyrus showing differences in the localization and intensity of immunoreactivity of GFAP+ astrocytes.
GFAP+ astrocytes are brown, the α7nAChRs are gray. Representative areas are displayed in the corresponding inserts (F-I). (F) In the CA1 alveus and
stratum oriens, intensely stained small somata of GFAP+/α7nAChRs astrocytes and networks were observed. (G) Throughout the stratum pyramidale,
large somata of GFAP+ astrocytes without α7nAChRs (arrows) were found dispersed throughout GFAP+ network. (H) Differences in the intensity of
immunoreactivity and the number of GFAP+ astrocytes were detected in the stratum lacunosum-moleculare (upper layer, strong staining) and the
molecular layer of the dentate gyrus (bottom layer, weak staining). (I) In the granular layer, weakly stained GFAP+ astrocytes and network (top layer)
were accompanied by very strong stained α7nAChR/GFAP+ astrocytes (bottom layer, gray). Videocapture was performed with ×10 (A, E) and ×20
(B-D, F-I) objective lenses magnification.
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Interestingly enough in vivo PET studies have shown
higher 11C-deuterium-L-deprenyl binding in brain of pa-
tients with mild cognitive impairment (MCI) than AD
and controls [17]. The observation might indicate a dif-
ference in astrocytes’ properties in early and later stages
of disease. In the present study, we observed a regional
difference between [3H]-L-deprenyl and [3H]-PK11195
in increase in binding sites in AD brains in comparison
to control brains. Interestingly, [3H]-L-deprenyl laminar
binding in the single AD case was found to be relatively
higher in the superficial cortical layers of the frontal
cortex in comparison to binding in the deeper cortical
layers. Immunohistochemical staining in the same AD case
confirmed abundant GFAP+ reactive astrocytes surroun-
ding Aβ plaques in the superficial layers of the frontal cor-
tex. These findings are in agreement with earlier reports on
the pattern of gliosis in AD in layers II to III and V [15].
It has been claimed that neurofibrillary tangles and Aβ
plaques should favor the same cortical layers as astroglia
[10,30,31,43]. The laminar pattern of [3H]-PIB binding
in cortex may thus suggest binding to additional forms
of Aβ than plaques. The high binding of both [3H]-PIB
and [3H]-deprenyl in the frontal cortex suggests that there
may be a close regional association between elevated
astroglia and fibrillar Aβ deposition, which is consistent
with our earlier observations in which a positive correl-
ation between regional brain [11C]-PIB retention, [3H]-PIB
binding, and the total number of GFAP+ immunoreactive
astrocytes was found in the same patient [6].
The hippocampus, however, revealed a different lam-
inar pattern, where high [3H]-L-deprenyl, but low [3H]-
PIB binding densities were observed in all hippocampal
subregions. The observation is in agreement with the
low amyloid but high gliosis in the hippocampus as
described by Beach and colleagues [15]. The hypothesis
of Rogers and Morrison [10] predict a cascade of path-
ology wherever there is a cascade of convergent cortical
input, and this is precisely the case Hyman et al. [44],
showed with their findings of cell-specific pathology
isolates the hippocampal formation in AD cases. Soluble
Aβ oligomers have received much attention and it is
argued that these assemblies play a major role in mediat-
ing neuronal damage in comparison to their insoluble
counterparts [1,45]. It is not known whether the concen-
tration of Aβ oligomers or intracellular Aβ is significantly
greater in the hippocampus compared to cortical regions
since studies to date characterizing various Aβ oligomer
assemblies in AD postmortem brain, have mostly been
performed using cortical brain extracts [46-48]. Non-
fibrillar Aβ aggregates are not readily detected in vivo with
the currently available amyloid PET tracers, and it is
possible that these soluble assemblies could underlie
the increased astrogliosis detected within the hippocam-
pus in the current study.
Astrocytes can take up Aβ in complex with apolipo-
protein E (ApoE) as well as degrade Aβ by neprilysin
[49-51]. Different types of astroglial cells can be distin-
guished in AD brain, including reactive, hypertrophic
astrocytes in the vicinity of Aβ plaques [10] and neuro-
fibrillary tangles (NFTs) [52], Aβ-containing astrocytes
that may possibly be involved in the removal of diffuse
plaques and fleecy amyloid [29,53,54], and functionally
impaired astrocytes with deficits in gene or protein
expression [49]. Atrophy of astrocytes occurring in the
early stage of AD is suggested to influence synaptic func-
tion and cognition [55].
Neuropathological changes in the brain during the
course of AD may disrupt the columnar organization of
the cerebral cortex, which in turn result in changes in
interlaminar astrocytic processes and modulation of their
function [15,56]. A decline in regional cerebral glucose me-
tabolism, determined by [18F]-fluorodeoxyglucose (FDG)
PET, in an AD patient 16 months before death correlated
with cortical neuronal loss and with intense staining of
GFAP+ cells in cortical areas at autopsy [57].
In addition to their role in neuroinflammatory pro-
cesses, astrocytes in the central nervous system also
provide structural and trophic support and are actively
involved in the regulation of neuronal and synaptic
activity with the purpose of maintaining overall brain
homeostasis [58,59]. Astrocytes that undergo both mor-
phological and structural changes during AD neuro-
degeneration neglect their neurosupportive functions as
pathogenesis advances, rendering neurons vulnerable to
excitotoxicity and oxidative stress [49,50,60,61]. Therefore,
it is likely that a strong inflammatory response triggered
by the neurodegenerative changes in the AD brain, accel-
erate and drive the degenerative pathology, contributing
to disease progression and chronicity.
An increase in regional [3H]-L-deprenyl binding was
recently reported in autopsy cases with lower Braak
stages compared to cases with higher Braak stages [62].
However, astrocytosis is a complex process and poorly
understood. Whether the reactive astrocytes in AD brain
can adopt different states of activation and whether
increased MAO-B activation in vivo or [3H]-L-deprenyl
binding in vitro reflects a certain type of astrocytes war-
rants future study.
In a recent study using rodent models of ischemic
stroke and neuroinflammation, Barres and colleagues
performed gene expression profiling analysis of popula-
tions of reactive astrocytes isolated at various time
points after induction, and demonstrated that reactive
astrocyte phenotype strongly depended on the type of
inducing injury [63].
The different laminar distribution patterns for Aβ and
astrocytosis in AD brain regions demonstrated in the
present study are indicative of two parallel processes,
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which may follow a different time course, and show a re-
gional variability that depends on the initiating insult
triggered in specific areas of the brain. Although the
postmortem imaging findings reported here were in line
with the homogenate binding studies, a weakness of the
current study is that the autoradiographical investigation
was carried out in solely a single AD case subject. How-
ever, this kind of technique examining laminar distribu-
tions in detail is a lengthy and time consuming process,
and does not allow simultaneous processing of many
cases. Our present findings in hemisphere brain have
also been validated in small tissue sections and gave
similar findings although the resolutions in the smaller
sections were lower (data not shown).
A growing number of studies have pointed to an
involvement of brain nAChRs and neuroinflammatory
processes in Aβ pathology. Both neurons and glia cells
express several nAChRs including the two major sub-
types in the brain, namely α4β2 and α7 nAChRs [64].
Earlier, we demonstrated that a reduction of α4β2
nAChRs in AD cortex is associated with high levels of fi-
brillar Aβ as well as higher molecular weight oligomeric
Aβ assemblies [6,46]. Interestingly, we observed in the
present study that increased distribution of fibrillar Aβ
in the frontal cortex was associated with lower laminar
[3H]-nicotine binding compared to other cortical regions,
suggesting that Aβ may induce a selective vulnerability of
some areas of cortical projections in the brain involving
specific or discrete neural systems.
While there is a reduced density of α7 nAChRs on
neuronal cells, an increased number of these receptors
have been found on astrocytes as measured in AD autopsy
brains [27,65,66]. It is known that astrocytes modulate
neuronal activity partly via ion channels and through the
neurotransmitter receptors they express [67]. The α7
nAChRs expressed on astrocytes could, thus, influence the
excitability of astrocytes and their ability to propagate
Ca2+-mediated signaling mechanisms. The amount of
soluble and/or non-soluble Aβ forms as well as their in-
ternal versus external localization [68] in different brain
regions could also influence intermediate processes be-
tween α7 nAChRs, glia and neurons, as implicated by
recent findings from our group [6,69].
Conclusions
In summary, we demonstrate an elevation in astrogliosis
both in areas with high and low fibrillar Aβ burden and
greater atrophy, which may suggest that different types
of reactive astrocytes are associated with the patho-
physiological processes in the AD brain. It is important
to continue to study these processes in vivo, in order to
obtain a better understanding of how astrocytes interact
with neuronal network function, and to resolve whether
these cells contribute to cognitive decline in AD.
Additional files
Additional file 1: Figure S1. Neuropathology in the brain obtained
from an Alzheimer’s disease case used for autoradiography studies
showing immunoreactivity in the frontal cortex and hippocampus,
respectively, for: (A-B) β-amyloid (Aβ), 6 F/3D; (C-D) hyperphosphorylated
tau protein, AT8; (E-F) activated microglia, CD68; and (G-H) reactive
astrocytes, glial fibrillary acidic protein (GFAP).
Additional file 2: Figure S2. Immunohistochemical staining of GFAP+
reactive astrocytes and Aβ aggregates in the hippocampus of the
Alzheimer’s disease case. In the hippocampus, both GFAP + astrocyte
somata and processes (brown) surrounding 6 F/3D-positive Aβ plaques
(red) (A) and glial fibrillary acidic protein-positive (GFAP+) astrocytes
containing intracellular vesicles with 6 F/3D Aβ (B) were detected. GFAP+
cells are indicated by arrows.
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